Medidata Named by IDC MarketScape™ as a Leader in Worldwide Life Sciences R&D RWD/RWE Data Platforms, Technology Solutions, and Consulting Services

What happened

Medidata, a Dassault Systèmes brand, was named a Leader in IDC MarketScape's 2026 assessment of worldwide life sciences R&D real-world data and real-world evidence platforms, technology solutions, and consulting services. Medidata was the only company focused exclusively on clinical trial technology placed in the Leaders category.

Confirmed

Global impact / market context

The recognition may help Medidata win and keep drug company customers, supporting software revenue and renewals. Being the only trial-focused vendor in the Leaders group could strengthen its sales pitch to research sponsors comparing real-world data platforms and consulting offerings.

Analyst inference

Drug companies increasingly want real-world data, which is health information gathered outside controlled trials, to guide research and regulatory decisions. Vendors combining trial data, artificial intelligence, and consulting compete for that spending, and third-party assessments can influence which suppliers buyers shortlist before negotiating contracts.

Analyst inference

What to watch

1. IDC highlighted Medidata's team of statisticians and data scientists using anonymized data from over 42,000 trials and 13 million patients, so watch how that data scale is used in future offerings. Confirmed
2. Medidata could use the Leader rating in marketing to trial sponsors, so watch whether it announces new customer wins or expanded contracts citing this assessment. Proposed
3. Rivals may respond with their own positioning or pricing, which could pressure sales cycles and revenue for clinical trial software, so watch competitive moves in real-world data platforms. Analyst inference

Evidence

• globenewswire.com